Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Cartesian Therapeutics Inc.

NASDAQ RNAC
$10.64 0.64 6.40%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 20 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
341.40M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
164.67M
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
-
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
25.90M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-40.59 %

Upcoming events Cartesian Therapeutics Inc.

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Cartesian Therapeutics Inc.

Stock analysis Cartesian Therapeutics Inc.

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-8.91 -1.30
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
-45.49 1.15
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-4.59 -0.75
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
4.92 0.42
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
175.82 -50.00

Price change Cartesian Therapeutics Inc. per year

9.15$ 25.14$
Min Max

Summary analysis Cartesian Therapeutics Inc.

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Cartesian Therapeutics Inc.

Revenue and net income Cartesian Therapeutics Inc.

All parameters

About company Cartesian Therapeutics Inc.

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA) for the treatment of autoimmune diseases, currently under Phase 2b clinical development for generalized myasthenia gravis, systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It develops Descartes-15, an autologous anti-BCMA mRNA CAR-T to treat autoimmune diseases such as relapsed/refractory multiple myeloma. Cartesian Therapeutics, Inc. is headquartered in Frederick, Maryland.
Address:
7495 New Horizon Way, Frederick, MD, United States, 21703
Company name: Cartesian Therapeutics Inc.
Issuer ticker: RNAC
ISIN: US8162121045
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2016-06-22
Sector: Healthcare
Industry: Biotechnology
Site: https://www.cartesiantherapeutics.com